

Financial Performance Month 3



Health Board agreed Financial Plan to deliver deficit of £25m, after savings of £34.2m. Impact of COVID-19 pandemic presents unprecedented significant risk to financial position. Without confirmation of further funding the planned financial position will not be achieved.

Month 3 position

- Month 3 YTD variance to breakeven £16.2m.
- Month 3 position is a favourable £0.6m (Month 2, £6.4m adverse) operational variance to plan (£10.0m YTD) following receipt of Quarter One WG funding for COVID-19 related Pay and Field Hospital set-up costs totalling £10.8m. Underlying in month variance was £11.4m excluding Welsh Government (WG) COVID-19 funding.
- Increase in the underlying position due to COVID-19 (£2.4m increase) further step up in workforce expenditure, the impact of WG Medical and Dental pay circular and loss of Non-Contracted Activity income arising from the COVID-19 pandemic.
- Additionality of costs incurred in Month 2 due to COVID-19 £12.2m (Month 2, £9.8m), with underspends repurposed of £2.0m.


Projection


- The savings requirement is at risk of non-delivery due to the operational focus being diverted to respond to COVID-19.
- The Operational Plans indicate a continuation of the significant costs incurred to date.
- Without confirmation of further funding the planned financial position will not be achieved.

Conclusions

- Alignment of strategic response to current demand modelling indicators between WG, Gold Command and operational teams.
- Clarity as to what current escalation measures can be safely and appropriately de-escalated/ decommissioned and which ceased/ deferred services/ activities can be recommenced.
- Continue to work with WG to understand future levels of additional revenue and capital funding available.









Key drivers of YTD position:

- Savings non-delivery (£7.9m): As a consequence of COVID-19, Directorates have been unable to execute or identify additional savings plans as efforts re-purposed to respond to the pandemic.
- Counties (£3.3m): The cost of setting up and operating the various Field Hospitals with the Health Board's localities are contained within this directorate. Set up costs of £2.5m for Pembrokeshire and Ceredigion funded by WG in Month 3; Carmarthenshire set up costs (£3.2m) expected to be recognised and funded in Month 4.
- Medicines Management (£1.5m): Pressures continue in the Category M and No Cheaper Source Obtainable (NCSO) drugs and in the use of Novel Anticoagulants (NOACs).
- **Planned Care (-£2.8m):** Underspend primarily driven by reduced activity in elective services which has dramatically reduced the non-pay element of Theatre spend.

Performance - YTD Financial Position









- Key drivers of YTD position:
- Savings non-delivery (£7.9m): As a direct consequence of COVID-19, Directorates have been unable to execute or identify additional savings plans as efforts re-purposed to respond to the pandemic.
- Other non-pay (£5.0m): Primarily driven by COVID-19 Field Hospital Premises costs (£5.1m).
- **Income (£2.0m):** Non Contracted Activity income has been impacted by the lockdown restrictions (£1.5m).
- Prescribing (£1.8m): Category M price increases; impact of NCSO basket increase; and increased use of NOACs.
- Care packages (£1.0m): Expedited discharge of CHC Patients at a premium rate and patients being placed in out of area accommodation.
- Pay (-£4.6m): Vacancies not filled both substantively and by Agency and Locum due to reduced demand.
- Drugs & Clinical supplies (-£1.8m): Primarily driven by reduced activity in elective services within Planned Care (-£2.8m), offset by increased spends as a result of COVID-19 (£1.3m).









Month 3 budgeted expenditure includes the WG allocation to retrospectively fund staff-related COVID-19 costs incurred during Q1 (£8.1m).


Workforce planning decisions required in relation to:


- Potential extension of the fixed term contracts in September, aligned to the Q3 Operational Plan;
- Re-configuration of medical rosters, reducing premium enhancement arrangements;
- Review of Directorate use of agency resource.

Nurse Agency expenditure continues to be significantly lower than average prior year levels (-£0.6m), although this has risen slightly in month as Nurses deployed to other departments to meet COVID-19 demand are now returning to substantive roles as activity re-commences in some Directorates.



Primary Care Prescribing





- Price increase from August 2019 of 34p per item.
 Pressure continues to increase despite budget uplift in 2020/21 Financial Plan.
- No Cheaper Source Obtainable (NCSO) drugs peaked in March 2020 (data available two months in arrears), which is expected to impact a minimum of several months of 2020/21.

Scrutiny - Power BI Platform



Finance Report


DATA REFRESHED: 7 JULY 2020

COVID No ☐ Yes

Period P03-21



In Month Variance: Actual against Forecast



Director of Finance review meetings already embedded into month-end closedown process, where part of scrutiny is understanding the reasons for deviation from forecast. This functionality is now on Power BI platform.




Movement due to increased costs for RROL - Everlight contract (£30k), increased drug costs (£20k) and X-ray purchases (£10k)

Scrutiny



The ledger total and sum of the component data feeds must equal each other, allowing for drill-down functionality from the ledger to the detail - the reconciliation process will scrutinise data sources and will likely trigger process improvement 'side' projects to improve the feeds.



Ledger Actual in Drugs

Scrutiny



Interactive Directorate dashboards

Introduction of nonfinancial drivers

Training programme (Finance and non-Finance)

Introduce additional levels of data mapping intelligence

Accelerate reporting of financial position to budget holders

Automate Executive
Summary
dashboard of HBwide position

Improved decision-making